RIPK1 and Alzheimer disease: Overall, our study suggests the possibility of inhibiting RIPK1 kinase for the treatment of ALS, AD, and also PD, to prevent cell death resulting downstream of myriad etiologies of neurodegeneration, but also suggests that metabolic regulations may provide additional benefit for therapeutic intervention.